SAN DIEGO, Calif. and SHANGHAI, Sept. 1, 2023 /PRNewswire/ — ABM Therapeutics, a clinical-stage biopharmaceutical company, today announced that the first patient has been successfully dosed in its multicenter Phase I study of ABM-1310 in patients with relapsed and drug resistant primary…